Peptide

FOXO4-DRI

Also known as

FOXO4 D-Retro-Inverso · FOXO4 DRI · FOX04-DRI · FOXO4DRI · Proxofim (vendor/colloquial discussion) · FOXO4 interference peptide (DRI) · FOXO4 D-retro-inverso peptide · FOXO4-p53 interference peptide

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Experimental senolytic peptide	Designed to disrupt the FOXO4–p53 partnership so certain senescent cells can die. The mechanism comes from cells and mice, not demonstrated human anti-aging results.
DRI / Proxofim	D-retro-inverso describes reversed amino-acid order with mirror-image building blocks intended to resist breakdown. Proxofim is another discussion name; injection routes are not interchangeable exposures.
In plain English	Senescent cells are damaged cells that have stopped dividing. People look for more energy, less pain or changes in aging skin, but feeling better does not establish that those cells were cleared.

Notes

A peptide designed to remove cells, rather than repair an injury directly. FOXO4 and p53 are proteins involved in cell survival. The peptide disrupts their partnership so certain senescent cells can undergo programmed cell death. That mechanism comes from cell and mouse experiments; feeling different does not demonstrate that cells were cleared. Baar et al. — Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging (Animal context · Accessed 2026-09-30)

FOXO4-DRI is an experimental peptide discussed for clearing senescent cells—the damaged, nondividing cells nicknamed “zombie cells.” Longevity users look for better energy, less pain or changes in aging skin. Actual logs include improvements, no noticeable benefit and uncomfortable reactions; a human anti-aging effect has not been established.

DRI describes its unusual construction. D-retro-inverso means reversed amino-acid order with mirror-image building blocks, intended to resist breakdown. “Proxofim” is another discussion name. Injected forms dominate the reports; oral claims and equal amounts by different injection routes do not establish equal exposure. FOXO4-DRI Peptide Benefits, Dosage & Side Effects (Secondhand community claim · Accessed 2026-09-30)

Less pain, easier movement and more energy. Earlier reports describe recovery, sleep and back-pain changes. A Reddit user described softer hand/foot nodules and improved movement, but also used several other peptides. These remain symptom reports, not proof of tissue repair or longevity. Any FOXO4-DRI Experiences? (Personal report · Accessed 2026-09-30)

Source context — Baar et al. — Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging: Abstract/record access only, not full methods; primary-paper dose/DRI chemistry not freshly verified here. No human efficacy or safety inference.

Source context — FOXO4-DRI Peptide Benefits, Dosage & Side Effects: Commercial influencer/affiliate article; Greenfield claim is secondhand, not original trial. Scientific and marketing claims are not credited as proof. Original /peptides/ URL redirects to /blog/.

Source context — Any FOXO4-DRI Experiences?: Pseudonymous, unverified products, extensive co-use, relative comment dates only. 'Mouse' euphemism in a reply is not a documented animal study. TA-1/antiviral outcomes from other replies are not FOXO4 outcomes.

What people notice

Pain, movement and energy	Some describe less pain, easier movement, sleep or energy changes. The nodule account also involved SS-31, KLOW and MOTS-c, with incomplete improvement later.
Nothing useful or worse recovery	Other logs report no meaningful benefit despite substantial amounts. A runner described better hip comfort alongside slower calf recovery and marked tiredness with rapamycin/metformin co-use.

Notes

Pain relief can coexist with incomplete improvement. The nodule reporter described soreness after nighttime use, then improved movement with SS-31, KLOW and MOTS-c in the sequence. Later, one larger hand nodule still limited finger extension. The result cannot be assigned to FOXO4-DRI alone. Any FOXO4-DRI Experiences? (Personal report · Accessed 2026-09-30)

No benefit can occur despite substantial amounts. Raveofthe90s described 20 mg across five days and a later single 10 mg vial with nothing meaningful to report. The July log recorded little beyond soreness and fatigue. Replies suggesting more cycles do not establish that persistence will produce a benefit. Any FOXO4-DRI Experiences? (Personal report · Accessed 2026-09-30) · I did FOXO4-DRI full dose (25mg x3) (Personal report · Accessed 2026-09-30)

Recovery can also feel worse. A LongeCity runner described better hip comfort alongside slower calf recovery and marked tiredness after a compressed course, with rapamycin and metformin co-use. Another participant reported no effect. Positive and negative impressions coexist within the same discussion. FOXO4 D-Retro-Inverso peptide group buy — page 17 (Personal report · Accessed 2026-09-30)

Source context — I did FOXO4-DRI full dose (25mg x3): Single early log with self-described CFS/brain fog; route not explicit; stopping other compounds, fasting and exercise confound observations. Dates retained as written and interpreted as July from entries, not inferred posting date.

Source context — FOXO4 D-Retro-Inverso peptide group buy — page 17: May 2018 uncontrolled accounts; prior extensive interventions and subjective interpretation. Hypotheses about tissue tightening, stem cells and bloodstream levels are not established.

Doses people talk about

Low-mg short pulses	Charts describe 2–3 mg or 3–5 mg under the skin every other day for three doses. Separate earlier accounts used 3 mg daily for six doses or every other day for six, with route unstated.
High pulses are separate	One author reported 28 mg every 48 hours for three administrations, route unstated. Another reported 35, 35 and 30 mg under the skin on consecutive days. The copied 25 mg IV figure was a mouse-scaling guess.
Long microgram charts	A circulated under-skin ladder lists 250 mcg/day for weeks 1–4, 375 for weeks 5–8 and 500 for weeks 9–16. A separate chart names 1 mg mornings, five days on/two off for about two weeks.
Intermediate accounts	Earlier reports also include about 1 mg under the skin, 1 mg every other day for about 20 days after divided first-day amounts, and 2 mg every other day for about 30 days. These are distinct experiments.

Notes

SubQ short pulses: 2–3 mg or 3–5 mg per administration. Community charts describe these separate lower-milligram bands every other day for three doses. SubQ means beneath the skin; mg means milligrams. They are reported patterns, not validated doses.

Other low-mg accounts: 3 mg daily ×6 or 3 mg every other day ×6. Earlier reports describe these separate finite courses without a specified route. One account also involved gonadorelin, a hormone-related peptide; another reported no negative effects. Those observations do not establish safety.

Higher pulses are a separate camp. A Rapamycin News author reported 28 mg every 48 hours, three administrations (84 mg total); the post does not specify route. Fight Aging's often-copied 25 mg figure was a mouse-to-human scaling guess for a 60 kg person using an IV (into a vein) framing, not a measured SubQ dose. FOXO4-DRI: notes from 12 days past 3x 28mg q48h FOXO4-DRI (Personal report · Accessed 2026-09-30) · How to Plan and Carry Out a Simple Self-Experiment, a Single Person Trial of Senolytic Peptide FOXO4-DRI (Community guide · Accessed 2026-09-30)

Some experiments depart sharply from those pulses. One LongeCity poster reported SubQ 35 mg, 35 mg, then 30 mg on consecutive days. A July 2026 Reddit log lists 3 mg initially, then 24, 27 and 26 mg—not precisely its “25 mg ×3” title. Its injection route is unclear. FOXO4 D-Retro-Inverso peptide group buy — page 17 (Personal report · Accessed 2026-09-30) · I did FOXO4-DRI full dose (25mg x3) (Personal report · Accessed 2026-09-30)

Long low-dose charts: 250 → 375 → 500 mcg daily. A circulated SubQ ladder assigns weeks 1–4, 5–8 and 9–16 respectively; 1,000 mcg equals 1 mg. Another chart says 1 mg mornings, five days on/two off for about two weeks. Neither chart is a measured response or an interchangeable version of a large pulse.

Low-dose and intermediate reports also exist. Earlier accounts include about 1 mg SubQ, 0.3 + 0.3 + 0.4 mg during the first 24 hours then 1 mg every other day for about 20 days, and 2 mg every other day for about 30 days. Community guides also span 3–25 mg per injection for 3–6 alternate-day administrations. These are distinct accounts, not a recommended range.

Source context — FOXO4-DRI: notes from 12 days past 3x 28mg q48h FOXO4-DRI: One uncontrolled account; route unstated in visible post; product unverified; no posted follow-up bloodwork in inspected stream. Planning a test does not establish clearance.

Source context — How to Plan and Carry Out a Simple Self-Experiment, a Single Person Trial of Senolytic Peptide FOXO4-DRI: Creator's theoretical self-experiment outline, not completed clinical trial or validated regimen. Mouse scaling is explicitly hypothetical; commercial sourcing/logistics and procedural instructions are omitted.

Half-life, onset & duration

Felt onset	One log describes pain within a minute and skin changes about ten days after the final dose. Other reports use first-day or 2–4-week checkpoints.
Felt duration	No dependable single-dose window. One person still felt different days after a three-day course; nodule changes were reported months after multiple treatments. Other logs describe hours of site pain or about a day and a half of flu-like symptoms.
Half-life	No reliable human value here. Hours-to-days claims reason from DRI breakdown resistance; 48–72-hour coverage is inferred from animal dosing calendars, not human blood measurements.

Notes

Immediate discomfort and delayed changes are different clocks. The August author described pain starting about a minute after injection, while skin changes appeared around ten days after the final dose. Neither observation identifies when senescent-cell clearance began. FOXO4-DRI: notes from 12 days past 3x 28mg q48h FOXO4-DRI (Personal report · Accessed 2026-09-30)

Hours, weeks—or no change. A LongeCity account described warmth and calm on the first day. Older reports use two-to-four-week checkpoints and gradual changes during longer ladders. Reddit logs also describe no discernible benefit after a course; there is no dependable onset window. FOXO4 D-Retro-Inverso peptide group buy — page 17 (Personal report · Accessed 2026-09-30) · Any FOXO4-DRI Experiences? (Personal report · Accessed 2026-09-30)

No dependable single-dose benefit duration. One LongeCity poster still felt different several days after a three-day course. The Reddit nodule account described changes months later after multiple treatments. Neither isolates FOXO4-DRI or supplies a reliable duration. FOXO4 D-Retro-Inverso peptide group buy — page 17 (Personal report · Accessed 2026-09-30) · Any FOXO4-DRI Experiences? (Personal report · Accessed 2026-09-30)

Adverse symptoms can last longer than the injection. The August log's site pain lasted hours and resolved by morning. Another Reddit poster described flu-like feelings for about a day and a half after SubQ use, while acknowledging uncertainty about whether the product was the DRI form. FOXO4-DRI: notes from 12 days past 3x 28mg q48h FOXO4-DRI (Personal report · Accessed 2026-09-30) · Experience with FOX04-DRI (Personal report · Accessed 2026-09-30)

“Hours to days” is persistence lore, not a measured half-life. Community explanations reason from DRI breakdown resistance. No reliable human clearance value was identified in the discussions reviewed. Half-life is the time for a measured amount to fall by half; it is not when a sensation fades.

48–72-hour coverage is inferred from dosing calendars. That older claim follows alternate-day or thrice-weekly mouse schedules, not blood measurements. Slower SubQ absorption and limited brain entry are also community explanations, not mapped human pharmacokinetics.

Source context — Experience with FOX04-DRI: Thread began June 2022; comments show relative dates, not exact dates. Special-Abalone1421 says product preceded DRI naming, leaving identity unclear.

Cycles people discuss

Pulse-and-wait customs	Guides describe 3–6 alternate-day injections and 1–3 courses yearly. Repeat timing guesses how fast senescence returns; it is not a tested maintenance interval.
Long ladders differ	Other charts pair a two-week course with 3–6 months off or use 12–16-week low-dose ladders. No comparison establishes which calendar works.

Notes

Short pulses followed by months off. Community guides describe 3–6 alternate-day injections, with 1–3 courses per year. Repeat timing is based on guesses about new senescence, not a tested maintenance interval.

Two-week courses and 12–16-week ladders are different approaches. The 1 mg chart pairs its short course with 3–6 months off and 2–3 courses yearly. Low-microgram ladders keep exposure going much longer; some low-mg anecdotes simply say on/off for months. No comparison establishes which calendar works.

Stacks

Other senolytics	Discussion includes rotation with dasatinib plus quercetin or fisetin, alongside cautions about simultaneous senolytic stacking. The rotation is community reasoning, not proven combination benefit.
Clear then rebuild narrative	MOTS-c, SS-31, Epitalon, GHK-Cu and NAD-related products appear in this narrative. Actual multi-peptide accounts cannot identify which substance caused improvement.
Rapamycin / metformin	Both accompanied the runner's mixed report of less hip discomfort, slower calf recovery and tiredness. This does not establish a useful or compatible pairing.

Notes

“Clear first, rebuild later” is stack reasoning. MOTS-c, SS-31, Epitalon, GHK-Cu and NAD-related products appear in that narrative. Others compare or rotate with dasatinib + quercetin or Fisetin and object to cost or simultaneous senolytic stacking. No controlled combination result validates the sequence. Any FOXO4-DRI Experiences? (Personal report · Accessed 2026-09-30)

Senolytic rotation: Alongside or alternating dasatinib + quercetin (D+Q) or high-dose fisetin pulses — different mechanisms (kinase/BCL pathways vs FOXO4–p53 peptide). [community]

Don’t combine same-week aggression (caution talk): Some longevity forums warn against stacking multiple strong senolytics simultaneously without spacing — theoretical clearance burden. [community]

Watch for

Pain and feeling ill	Burning, soreness, nausea, fatigue, headache and stomach upset occur. Calling them a clearance reaction does not verify that senescent cells were removed.
Wrong form or impurities	The discussion flags amino-acid identity, impurities and residual manufacturing salts. Pain does not prove activity; purity claims do not establish sterility or safety.
Clearing cells can have costs	Particular rodent lung-disease models worsened with senolytic interventions. Healing, infection, cancer, immune compromise and pregnancy concerns remain unresolved in human anecdotes.

Notes

Pain, fatigue and stomach symptoms deserve their own explanation. User logs include burning, soreness, nausea and fatigue; earlier reports also describe headache and stomach upset. Calling these a “clearance reaction” is an interpretation, not a verified cause. Experience with FOX04-DRI (Personal report · Accessed 2026-09-30) · I did FOXO4-DRI full dose (25mg x3) (Personal report · Accessed 2026-09-30)

Vial identity is a major uncertainty. User guides raise impurities, the wrong amino-acid form and residual TFA salts—chemical residues from manufacturing. Purity claims do not establish identity, sterility or safety; lack of benefit is not automatically underdosing, and pain does not prove an active product. How to Plan and Carry Out a Simple Self-Experiment, a Single Person Trial of Senolytic Peptide FOXO4-DRI (Community guide · Accessed 2026-09-30)

Clearing senescent cells is not uniformly beneficial. Born and colleagues found worse blood-vessel pressure and related changes in the lungs with senolytic interventions, including FOXO4-DRI, in particular rodent models. This is an animal warning about disease context, not a measured human risk rate. Born et al. — Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression (Animal context · Accessed 2026-09-30)

Healing, cancer and immune context complicate the idea. The existing discussion flags active wounds/surgery, infection, malignancy, pregnancy/breastfeeding and immune compromise. Senescence and p53 have useful as well as harmful roles; the anecdotes do not settle safety, long-term effects or interactions.

Source context — Born et al. — Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression: Primary abstract only; publisher full text failed. Disease-specific animal results cannot quantify human risk or prove every senolytic has identical effects.

Full notes

What FOXO4-DRI actually is

A peptide designed to remove cells, rather than repair an injury directly. FOXO4 and p53 are proteins involved in cell survival. The peptide disrupts their partnership so certain senescent cells can undergo programmed cell death. That mechanism comes from cell and mouse experiments; feeling different does not demonstrate that cells were cleared. Animal context
DRI describes its unusual construction. D-retro-inverso means reversed amino-acid order with mirror-image building blocks, intended to resist breakdown. “Proxofim” is another discussion name. Injected forms dominate the reports; oral claims and equal amounts by different injection routes do not establish equal exposure. Jay Campbell Community

What people hope to gain

Less pain, easier movement and more energy. Earlier reports describe recovery, sleep and back-pain changes. A Reddit user described softer hand/foot nodules and improved movement, but also used several other peptides. These remain symptom reports, not proof of tissue repair or longevity. Community Personal report
Skin, hair and testosterone hopes need different evidence. Community interest extends to skin, hair and hormones. The underlying fur recovery and testosterone findings came from mice; they do not establish a human cosmetic or hormonal benefit. Community Animal context Animal context

Doses people discuss

Amounts describe discussion and self-experimentation, not a personal regimen. Per-injection amounts and whole-course totals are kept separate.

SubQ short pulses: 2–3 mg or 3–5 mg per administration. Community charts describe these separate lower-milligram bands every other day for three doses. SubQ means beneath the skin; mg means milligrams. They are reported patterns, not validated doses. Community
Other low-mg accounts: 3 mg daily ×6 or 3 mg every other day ×6. Earlier reports describe these separate finite courses without a specified route. One account also involved gonadorelin, a hormone-related peptide; another reported no negative effects. Those observations do not establish safety. Community
Influencer guide: 3 mg SubQ every other day for six days. Jay Campbell attributes this to Ben Greenfield. The page contains affiliate promotion; a creator's schedule does not establish human effectiveness. Jay Campbell
Higher pulses are a separate camp. A Rapamycin News author reported 28 mg every 48 hours, three administrations (84 mg total); the post does not specify route. Fight Aging's often-copied 25 mg figure was a mouse-to-human scaling guess for a 60 kg person using an IV (into a vein) framing, not a measured SubQ dose. Personal report Community guide
Some experiments depart sharply from those pulses. One LongeCity poster reported SubQ 35 mg, 35 mg, then 30 mg on consecutive days. A July 2026 Reddit log lists 3 mg initially, then 24, 27 and 26 mg—not precisely its “25 mg ×3” title. Its injection route is unclear. Personal report Personal report
Long low-dose charts: 250 → 375 → 500 mcg daily. A circulated SubQ ladder assigns weeks 1–4, 5–8 and 9–16 respectively; 1,000 mcg equals 1 mg. Another chart says 1 mg mornings, five days on/two off for about two weeks. Neither chart is a measured response or an interchangeable version of a large pulse. Community
Low-dose and intermediate reports also exist. Earlier accounts include about 1 mg SubQ, 0.3 + 0.3 + 0.4 mg during the first 24 hours then 1 mg every other day for about 20 days, and 2 mg every other day for about 30 days. Community guides also span 3–25 mg per injection for 3–6 alternate-day administrations. These are distinct accounts, not a recommended range. Community

Half-life

“Hours to days” is persistence lore, not a measured half-life. Community explanations reason from DRI breakdown resistance. No reliable human clearance value was identified in the discussions reviewed. Half-life is the time for a measured amount to fall by half; it is not when a sensation fades. Community
48–72-hour coverage is inferred from dosing calendars. That older claim follows alternate-day or thrice-weekly mouse schedules, not blood measurements. Slower SubQ absorption and limited brain entry are also community explanations, not mapped human pharmacokinetics. Community

Onset: when people notice something

Immediate discomfort and delayed changes are different clocks. The August author described pain starting about a minute after injection, while skin changes appeared around ten days after the final dose. Neither observation identifies when senescent-cell clearance began. Personal report
Hours, weeks—or no change. A LongeCity account described warmth and calm on the first day. Older reports use two-to-four-week checkpoints and gradual changes during longer ladders. Reddit logs also describe no discernible benefit after a course; there is no dependable onset window. Personal report Community Personal report

Duration: how long changes last

No dependable single-dose benefit duration. One LongeCity poster still felt different several days after a three-day course. The Reddit nodule account described changes months later after multiple treatments. Neither isolates FOXO4-DRI or supplies a reliable duration. Personal report Personal report
Adverse symptoms can last longer than the injection. The August log's site pain lasted hours and resolved by morning. Another Reddit poster described flu-like feelings for about a day and a half after SubQ use, while acknowledging uncertainty about whether the product was the DRI form. Personal report Personal report

Cycles and time off

Short pulses followed by months off. Community guides describe 3–6 alternate-day injections, with 1–3 courses per year. Repeat timing is based on guesses about new senescence, not a tested maintenance interval. Community
Two-week courses and 12–16-week ladders are different approaches. The 1 mg chart pairs its short course with 3–6 months off and 2–3 courses yearly. Low-microgram ladders keep exposure going much longer; some low-mg anecdotes simply say on/off for months. No comparison establishes which calendar works. Community

Good to know

Pain, fatigue and stomach symptoms deserve their own explanation. User logs include burning, soreness, nausea and fatigue; earlier reports also describe headache and stomach upset. Calling these a “clearance reaction” is an interpretation, not a verified cause. Community Personal report Personal report
Vial identity is a major uncertainty. User guides raise impurities, the wrong amino-acid form and residual TFA salts—chemical residues from manufacturing. Purity claims do not establish identity, sterility or safety; lack of benefit is not automatically underdosing, and pain does not prove an active product. Community guide Community
Clearing senescent cells is not uniformly beneficial. Born and colleagues found worse blood-vessel pressure and related changes in the lungs with senolytic interventions, including FOXO4-DRI, in particular rodent models. This is an animal warning about disease context, not a measured human risk rate. Animal context
Healing, cancer and immune context complicate the idea. The existing discussion flags active wounds/surgery, infection, malignancy, pregnancy/breastfeeding and immune compromise. Senescence and p53 have useful as well as harmful roles; the anecdotes do not settle safety, long-term effects or interactions. Community

What actual discussions add

No benefit can occur despite substantial amounts. Raveofthe90s described 20 mg across five days and a later single 10 mg vial with nothing meaningful to report. The July log recorded little beyond soreness and fatigue. Replies suggesting more cycles do not establish that persistence will produce a benefit. Personal report Personal report
Pain relief can coexist with incomplete improvement. The nodule reporter described soreness after nighttime use, then improved movement with SS-31, KLOW and MOTS-c in the sequence. Later, one larger hand nodule still limited finger extension. The result cannot be assigned to FOXO4-DRI alone. Personal report
Recovery can also feel worse. A LongeCity runner described better hip comfort alongside slower calf recovery and marked tiredness after a compressed course, with rapamycin and metformin co-use. Another participant reported no effect. Positive and negative impressions coexist within the same discussion. Personal report
“Clear first, rebuild later” is stack reasoning. MOTS-c, SS-31, Epitalon, GHK-Cu and NAD-related products appear in that narrative. Others compare or rotate with dasatinib + quercetin or Fisetin and object to cost or simultaneous senolytic stacking. No controlled combination result validates the sequence. Community Personal report
Cost and uncertain products complicate comparisons. Older users contrast expensive high-milligram courses with cheaper D+Q or Fisetin experiments, while low-dose users dispute whether large pulses are necessary. No amount of money spent verifies active product, and subjective benefits cannot identify a minimum effective dose. Community Community

Where the animal numbers belong

The foundational results were cells and mice. Baar's 2017 work reports changes in mouse fur, fitness and kidney function. It does not establish human benefit. The 5 mg/kg intraperitoneal (into the abdominal cavity) pulse quoted in self-experiment guides remains mouse efficacy exposure—not human dosing or a half-life. Animal context Community guide